Entropy Neurodynamics Limited
0.03
AUD
0.00
(0.00%)
ISIN
AU0000433583
Return %
Stock
S&P 500
1Y
-13.51
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Jason Carroll
- Full Time Employees
- 4
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Bio101 Financial Advisory Pty Ltd Melbourne VIC Australia 3123
- IPO Date
- Nov 11, 2025
- Website
- entropyneurodynamics.com
- Similar Companies
- Business
- Entropy Neurodynamics Limited is a clinical‑stage biopharmaceutical company focused on developing psilocin-based formulations administered in combination with psychotherapy to treat neuropsychiatric and other unmet medical conditions. The company advances IV-infused psilocin programs designed to address rapid onset, controlled depth and duration of psychedelic experiences, with a pipeline targeting disorders such as binge eating disorder and chronic pain conditions, and plans to expand into additional neurological indications. Headquartered in Sydney, Australia, the company operates across Australia, the United States, Canada, and Switzerland, and maintains strategic partnerships and collaborations to support clinical development and regulatory pathways. Founded in 2016, Entropy Neurodynamics Limited develops and manufactures proprietary delivery platforms and pharmaceutical formulations, including neuropsychiatric therapeutics leveraging psilocybin/psilocin chemistry, with a focus on rapid onset and controlled therapeutic experiences. The company’s core products and services include IV-infused psilocin formulations for clinical use; psychotherapy integration protocols; regulatory strategy and clinical trial design support; and long‑term pipeline development through its NeuroSyn‑Modulate platform, aimed at expanding indications in neurology and mood disorders. Recent activities involve pursuing strategic alliances with research institutions and contract development partners, advancing Phase 2 clinical programs, considering potential acquisitions or collaborations to broaden its asset base, and exploring geographic expansion to accelerate trial enrollment and commercialization readiness.
Company News
Rio Tinto’s $260 billion copper pivot: A calculated bet on the energy transition
Entropy Neurodynamics reports early symptom improvements in first TRP-8803 binge eating disorder patient
MedPal AI rises 8% on pharmacy automation breakthrough
Small Cap Watch: Small Ordinaries firmer as gold, rare earths and biotech updates drive the morning news